Home

GCP Asset Backed Income

RNS

Investor Report as at 30 September 2018

, category: Results

Download PDF(opens in a new tab)
RNS Number : 9439F
GCP Asset Backed Income Fund Ltd
01 November 2018

GCP Asset Backed Income Fund Limited

 (the "Company" or "GCP Asset Backed")  

LEI: 213800FBBZCQMP73A815

Investor Report as at 30 September 2018

1 November 2018

GCP Asset Backed, which invests in asset backed loans, is pleased to announce the publication of its investor report, which is available at www.graviscapital.com/funds/gcp-asset-backed/literature.

For further information, please contact:

Gravis Capital Management Limited

                                                                                                                                                +44 (0) 20 3405 8500

David Conlon                           david.conlon@graviscapital.com 

Dion Di Miceli                          dion.dimiceli@graviscapital.com 

Cenkos Securities plc

                                                                                                                                                +44 (0)20 7397 8900

Tom Scrivens                           tscrivens@cenkos.com 

Oliver Packard                         opackard@cenkos.com 

Sapna Shah                               sshah@cenkos.com 

Notes to Editors

The Company

GCP Asset Backed is a closed ended investment company traded on the Main Market of the London Stock Exchange. Its investment objective is to generate attractive risk-adjusted returns primarily through regular, growing distributions and modest capital appreciation over the long term.

The Company seeks to meet its investment objective by making investments in a diversified portfolio of predominantly UK based asset backed loans which have contracted, predictable medium to long term cash flows and/or physical assets.  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEAXEFDDSPFFF

Back to announcements

Contact us